In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: Implications for Parkinson's Disease

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 80-84

  Abin Carriquiry, J Andrés ^a   Costa, Gustavo ^a   Urbanavicius, Jessika ^a   Cassels, Bruce K ^b   Rebolledo Fuentes, Marco ^b   Wonnacott, Susan ^c   Dajas, Federico ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b UNIVERSITY OF CHILE   (Chile)

^c University of Bath   (United Kingdom)

Author keywords

6 Hydroxydopamine; Cytisine; Dopamine; Neuroprotection; Nicotinic acetylcholine receptor; Parkinson's Disease

Indexed keywords

3 BROMOCYTISINE; 5 BROMOCYTISINE; ASCORBIC ACID; CHLORISONDAMINE; CYTISINE; CYTISINE DERIVATIVE; DOPA; DOPAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DYSKINESIA; IN VIVO STUDY; MALE; MICRODIALYSIS; NERVE DEGENERATION; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PLANT; PRIORITY JOURNAL; RAT; SOPHORA;

ALKALOIDS; ANIMALS; ANTIPARKINSON AGENTS; AZOCINES; BRIDGED COMPOUNDS; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICRODIALYSIS; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; NICOTINE; NICOTINIC AGONISTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; RECEPTORS, PRESYNAPTIC; SUBSTANTIA NIGRA;

EID: 47549105878     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.013     Document Type: Article

References (46)

1. Abin-Carriquiry J.A., McGregor-Armas R., Costa G., Urbanavicius J., and Dajas F. Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra. Neurotox. Res. 4 (2002) 133-139
2. Abin-Carriquiry J.A., Voutilainen M.H., Barik J., Cassels B.K., Iturriaga-Vasquez P., Bermudez I., Durand C., Dajas F., and Wonnacott S. C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists. Eur. J. Pharmacol. 536 (2006) 1-11
3. Baron J.A. Cigarette smoking and Parkinson's disease. Neurology 36 (1986) 1490-1496
4. Baron J.A. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull. 52 (1996) 58-73
5. Bozzi Y., and Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci. 29 (2006) 167-174
6. Cassels B.K., Bermudez I., Dajas F., Abin-Carriquiry J.A., and Wonnacott S. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. Drug Discov. Today 10 (2005) 1657-1665
7. Clarke P.B., Hommer D.W., Pert A., and Skirboll L.R. Electrophysiological actions of nicotine on substantia nigra single units. Br. J. Pharmacol. 85 (1985) 827-835
8. Costa G., Abin-Carriquiry J.A., and Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888 (2001) 336-342
9. Dajas-Bailador F., and Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci. 25 (2004) 317-324
10. Gorell J.M., Rybicki B.A., Johnson C.C., and Peterson E.L. Smoking and Parkinson's disease: a dose-response relationship. Neurology 52 (1999) 115-119
11. Grady S., Marks M.J., Wonnacott S., and Collins A.C. Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59 (1992) 848-856
12. Hejmadi M.V., Dajas-Bailador F., Barns S.M., Jones B., and Wonnacott S. Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes. Mol. Cell. Neurosci. 24 (2003) 779-786
13. Houlihan L.M., Slater Y., Guerra D.L., Peng J.H., Kuo Y.P., Lukas R.J., Cassels B.K., and Bermudez I. Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors. J. Neurochem. 78 (2001) 1029-1043
14. Iida M., Miyazaki I., Tanaka K., Kabuto H., and Iwata-Ichikawa E. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838 (1999) 51-59
15. Jonnala R.R., and Buccafusco J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. 66 (2001) 565-572
16. Kaiser S., and Wonnacott S. Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58 (2000) 312-318
17. Khwaja M., McCormack A., McIntosh J.M., Di Monte D.A., and Quik M. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J. Neurochem. 100 (2007) 180-190
18. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., and Akaike A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42 (1997) 159-163
19. Kihara T., Shimohama S., Urushitani M., Sawada H., Kimura J., Kume T., Maeda T., and Akaike A. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792 (1998) 331-334
20. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
21. Lichtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E., and Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology 21 (1982) 963-968
22. Marshall D.L., Redfern P.H., and Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68 (1997) 1511-1519
23. O'Neill M.J., Murray T.K., Lakics V., Visanji N.P., and Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 399-411
24. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), (Academic Press)
25. Puttfarcken P.S., Jacobs I., and Faltynek C.R. Characterization of nicotinic acetylcholine receptor-mediated [(3)H]-dopamine release from rat cortex and striatum. Neuropharmacology 39 (2000) 2673-2680
26. Quarta D., Ciruela F., Patkar K., Borycz J., Solinas M., Lluis C., Franco R., Wise R.A., Goldberg S.R., Hope B.T., Woods A.S., and Ferre S. Heteromeric nicotinic acetylcholine-dopamine autoreceptor complexes modulate striatal dopamine release. Neuropsychopharmacology 32 (2007) 35-42
27. Quik M., Chen L., Parameswaran N., Xie X., Langston J.W., and McCallum S.E. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26 (2006) 4681-4689
28. Quik M., Parameswaran N., McCallum S.E., Bordia T., Bao S., McCormack A., Kim A., Tyndale R.F., Langston J.W., and Di Monte D.A. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98 (2006) 1866-1875
29. Quik M., Bordia T., and O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol. 74 (2007) 1224-1234
30. Quik M., Cox H., Parameswaran N., O'Leary K., Langston J.W., and Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol. 62 6 (2007) 588-596
31. Quik M., O'Neill M., and Perez X.A. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci. 28 (2007) 229-235
32. Rapier C., Lunt G.G., and Wonnacott S. Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation. J. Neurochem. 54 (1990) 937-945
33. Schapira A.H. Dopamine agonists and neuroprotection in Parkinson's disease. Eur. J. Neurol. 9 3 (2002) 7-14
34. Scheller D., Chan P., Li Q., Wu T., Zhang R., Guan L., Ravenscroft P., Guigoni C., Crossman A.R., Hill M., and Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. 203 (2007) 415-422
35. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 81 (2007) 29-44
36. Slater Y.E., Houlihan L.M., Maskell P.D., Exley R., Bermudez I., Lukas R.J., Valdivia A.C., and Cassels B.K. Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 44 (2003) 503-515
37. 2+ acts by two separate pathways to modulate the supply of release-competent vesicles in chromaffin cells. Neuron 20 (1998) 1243-1253
38. Stevens C.F., and Wesseling J.F. Activity-dependent modulation of the rate at which synaptic vesicles become available to undergo exocytosis. Neuron 21 (1998) 415-424
39. Stevens T.R., Krueger S.R., Fitzsimonds R.M., and Picciotto M.R. Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. J. Neurosci. 23 (2003) 10093-10099
40. Turner T.J. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J. Neurosci. 24 (2004) 11328-11336
41. Urbanavicius J., Ferreira M., Costa G., Abin-Carriquiry J.A., Wonnacott S., and Dajas F. Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum. J. Neurochem. 102 (2007) 723-730
42. Visanji N.P., O'Neill M.J., and Duty S. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51 (2006) 506-516
43. Wonnacott S., Kaiser S., Mogg A., Soliakov L., and Jones I.W. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 393 (2000) 51-58
44. Wonnacott S., Barik J., Dickinson J., and Jones I.W. Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J. Mol. Neurosci. 30 (2006) 137-140
45. Zhou F.M., Liang Y., and Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci. 4 (2001) 1224-1229
46. Zoli M., Moretti M., Zanardi A., McIntosh J.M., Clementi F., and Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22 (2002) 8785-8789